

FUNDED PROJECTS KWF PROGRAMME RESEARCH & IMPLEMENTATION CALL 2016-II

RESEARCH PROJECTS

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Tumor type	Mission Goal(s)	Assigned Funder	Approved budget
10529	Spatiotemporal dynamics of therapy response and resistance in gastrointestinal malignancies	dr. Louis Vermeulen	Academic Medical Center	Center of Experimental and Molecular Medicine	Basic research	Pancreatic Cancer	Basic research;More cure;Better quality of life		€ 578.196,00
10713	Discovery of the dominant repertoire of polymorphic targets in anti-tumor immunity after allogeneic stem cell transplantation	dr. Marieke Griffioen	Leiden University Medical Center	Hematology	Basic research	Blood Cancer;Leukemia;Non-Hodgkin's Lymphoma	Basic research;More cure;Better quality of life		€ 559.816,00
10726	Role of CD161+ T-cells in cancer patients	prof. Sjoerd van der Burg	Leiden University Medical Center	Clinical Oncology	Basic research	Head and Neck Cancer	Basic research;More cure		€ 584.120,00
10815	Additional potentially targetable neo-epitopes for immunotherapy, failure to see or to present?	prof. Sjoerd van der Burg	Leiden University Medical Center	Clinical Oncology	Basic research	Melanoma;Not Site-Specific Cancer	Basic research;More cure		€ 620.638,00
10835	Impeding SUMO signal transduction as a novel anti-cancer strategy	dr. Alfred Vertegaal	Leiden University Medical Center	Molecular Cell Biology	Basic research	Breast Cancer;Pancreatic Cancer;Sarcoma (soft tissue)	Basic research;More cure		€ 528.893,00
10813	Comprehensive genetic monitoring of MDS and AML (sub)clones in response to therapy	dr. Leonie Kroeze	Radboud University Medical Center	Laboratory Medicine	Basic research	Leukemia	Basic research;More cure;Better quality of life		€ 508.305,50
10535	The role of translation elongation in models of intestinal cancer	dr. William Faller	The Netherlands Cancer Institute	Molecular Genetics	Basic research	Small Intestine Cancer	Basic research;More cure		€ 591.403,50
10623	Dissecting how tumor-associated myeloid cells counteract chemotherapy response of breast cancer	dr. Karin de Visser	The Netherlands Cancer Institute	Immunology	Basic research	Breast Cancer	Basic research;More cure;Better quality of life		€ 549.510,00
10796	Role of DNA Damage Tolerance Pathways in Genome Maintenance, Tissue Homeostasis, and Cancer Suppression	dr. Heinz Jacobs	The Netherlands Cancer Institute	Biological Stress Response	Basic research	Not Site-Specific Cancer	Basic research		€ 583.902,00
10685	Biomarkers for chemotherapy sensitivity and prognosis of 1p/19q non-codeleted anaplastic glioma: analysis of the intercontinental CATNON trial	prof. Martin van den Bent	Erasmus University Medical Center Rotterdam	Neurology	Credentialing	Brain Tumor	More cure;Better quality of life		€ 456.138,50
10758	Risk prediction, screening and therapy of breast cancer in women from CHEK2 c.1100delC families in the Netherlands	dr. Maartje Hooning	Erasmus University Medical Center Rotterdam	Medical Oncology	Credentialing	Breast Cancer	More cure;Better quality of life	Pink Ribbon	€ 549.769,00
10613	Identification of patients with resectable gastro-esophageal adenocarcinoma with best chances of response to immune checkpoint inhibition therapy	dr. Nicole van Grieken	VU University Medical Centre	Pathology (VUmc CCA)	Credentialing	Oesophageal Cancer;Stomach Cancer	Basic research;More cure;Better quality of life		€ 678.480,50
10781	Cancer risk assessment of anal intraepithelial neoplasia using DNA methylation markers	dr. Renske Steenbergen	VU University Medical Centre	Pathology (VUmc CCA)	Credentialing	Anal Cancer	Less cancer;More cure;Better quality of life		€ 546.269,20
10595	Development of patient specific treatment planning to enhance and optimize clinical effectiveness of hyperthermic intraperitoneal chemotherapy in colorectal cancer patients	dr. Hans Crezee	Academic Medical Center	Radiation Oncology (Radiotherapy)	Creation of modality	Colon and Rectal Cancer	More cure		€ 563.765,00
10651	Using Molecular Subtypes to predict anti-EGFR Responses in metastatic Colorectal Cancer	dr. Louis Vermeulen	Academic Medical Center	Center of Experimental and Molecular Medicine	Creation of modality	Colon and Rectal Cancer	Basic research;More cure;Better quality of life		€ 557.347,00
10666	Photodynamic therapy of incurable perihilar cholangiocarcinoma	dr. Michal Heger	Academic Medical Center	Surgery	Creation of modality	Gallbladder Cancer ;Gastro-intestinal Tract ;Liver Cancer	Basic research;More cure		€ 508.079,00
10761	Which treatment is most effective for the individual patient suffering from Chronic Cancer-related Fatigue? Network theory and the patient perspective.	dr. Marije van der Lee	Helen Dowling Instituut	Scientific Research	Creation of modality	Not Site-Specific Cancer	Better quality of life		€ 420.831,00
10603	Novel statistical methods for efficient identification of biomarkers for personalized cancer treatment	dr. Michael Hauptmann	The Netherlands Cancer Institute	Psychosocial Research and Epidemiology	Creation of modality	Breast Cancer	More cure;Better quality of life		€ 400.299,50
10755	SELECT - Stromal Enhancement on breast MRI as biomarker for survival with EndoCrine Therapy	dr. Kenneth Gilhuijs	UMC Utrecht	Imaging	Creation of modality	Breast Cancer	More cure;Better quality of life		€ 480.462,00
10650	Autologous stem cell therapy for cancer treatment induced hypothyroidism	prof. Rob Coppes	University Medical Center Groningen	Radiotherapy	Creation of modality	Parathyroid Cancer;Thyroid Cancer	Better quality of life		€ 528.937,25
10673	Towards prediction of the outcome of cancer immunotherapy	prof. Carl Figdor	Radboud University Medical Center	Tumor Immunology	Preclinical	Melanoma	More cure;Better quality of life		€ 699.474,00
10795	Perioperative systemic therapy in patients undergoing cytoreductive surgery with HIPEC for peritoneal metastases of colorectal cancer: the CAIRO6 study.	dr. Ignace de Hingh	Catharina Ziekenhuis Eindhoven	Surgery	Clinical	Colon and Rectal Cancer Gastrointestinal Tract	More cure;Better quality of life		€ 608.598,10

10823	Is ESR1 mutational status measured in cell-free DNA associated with outcome to first-line taxane-based chemotherapy in ER-positive HER2-negative MBC patients?	prof. Stefan Sleijfer	Erasmus University Medical Center Rotterdam	Medical Oncology	Clinical	Breast Cancer	More cure;Better quality of life		€	391.719,50
10825	Neoadjuvant chemoradiotherapy plus standard surgery versus active surveillance for oesophageal cancer (SANO-trial)	prof.dr. Jan van Lanschot	Erasmus University Medical Center Rotterdam	Surgery	Clinical	Gastrointestinal Tract ;Oesophageal Cancer	Better quality of life		€	867.255,95
10845	Follow-up after surgery for colorectal liver metastases: the randomized controlled, multicentre FUTURE trial.	prof. Kees Verhoef	Erasmus University Medical Center Rotterdam	Surgery	Clinical	Colon and Rectal Cancer	Better quality of life		€	526.070,30
10674	A nurse-led sexual rehabilitation programme for women with gynaecological cancers receiving radiotherapy: a randomized multicentre trial	dr. Moniek ter Kuile	Leiden University Medical Center	Gynaecology	Clinical	Genital System, Female	Better quality of life	Alpe d'HuZes	€	513.061,55
10606	Comprehensive functional salivary gland management to avoid an iatrogenic dry mouth	dr. Wouter Vogel	The Netherlands Cancer Institute	Diagnostic Oncology	Clinical	Head and Neck Cancer;Not Site-Specific Cancer ;Thyroid Cancer	Better quality of life		€	520.258,50
10747	Improving the outcome of breast cancer surgery by real time assessment of resection margins using Hyperspectral Imaging	prof. Theodoor Ruers	University of Twente	MIRA - Institute for Biomedical Technology and Technical Medicine	Clinical	Breast Cancer	More cure;Better quality of life		€	430.849,80

Total funding Research Projects (28 projects): € 15.352.449,65

YOUNG INVESTIGATOR GRANTS

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Tumor type	Mission Goal(s)	Assigned Funder	Approved budget	
10620	The ImmuNet: Integrating Immunological Parameters for Personalized Cancer Therapy	dr. Johannes Textor	Radboud University Medical Center	Tumor Immunology	Basic research	Melanoma	Basic research;More cure;Better quality of life	Alpe d'HuZes	€	517.449,00
10658	Improving the effects of standard of care therapy in glioma by modulating tumor-associated macrophages and microglia functions	dr. Leila Akkari	The Netherlands Cancer Institute	Immunology	Basic research	Brain Tumor	Basic research;More cure	Alpe d'HuZes	€	521.467,40
10709	Exploring Galectin-9 and its signaling pathway as new tumor-selective cytotoxic drug in acute myeloid leukemia (AML)	MSc Valerie Wiersma	University Medical Center Groningen	Hematology	Basic research	Blood Cancer;Leukemia	Basic research;More cure	Alpe d'HuZes	€	509.495,00
10701	Cohesion weakness: a unique cancer vulnerability of unknown origin	dr. Job de Lange	VU University Medical Centre	Clinical Genetics (VUmc CCA)	Basic research	Bladder Cancer;Breast Cancer ;Head and Neck Cancer ;Leukemia	Basic research;More cure	Alpe d'HuZes	€	562.356,54
10817	Mass spectrometry as a novel ultra-sensitive platform to measure minimal residual disease in serum of patients with multiple myeloma	dr. Joannes Jacobs	Radboud University Medical Center	Laboratory Medicine	Creation of modality	Myeloma	More cure;Better quality of life	Alpe d'HuZes	€	510.016,80
10706	The effectiveness of online cognitive behavioral therapy for insomnia compared to no intervention on sleep-efficiency in adolescent childhood cancer survivors	dr. Raphaela van Litsenburg	VU University Medical Centre	Pediatric Oncology-hematology (VUmc CCA)	Clinical	Not Site-Specific Cancer	Better quality of life	Alpe d'HuZes	€	453.237,40

Total funding Young Investigator Grants (6 projects): € 3.074.022,14

CONSORTIA

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Tumor type	Mission Goal(s)	Assigned Funder	Approved budget	
10602	Improving treatment decisions in colorectal cancer: the role of tumor budding	prof. Iris Nagtegaal	Radboud University Medical Center	Pathology	Creation of modality	Colon and Rectal Cancer	More cure;Better quality of life		€	1.600.246,10
10616	Towards an improved preoperative risk classification in endometrial carcinoma, a European collaborative network study	dr. Johanna Pijnenborg	Radboud University Medical Center	Obstetrics and Gynaecology	Creation of modality	Endometrial Cancer	More cure;Better quality of life		€	240.072,20
10645	INVUSE: Investigation of variants of uncertain clinical significance for use in clinical practice	prof. Hein te Riele	The Netherlands Cancer Institute	Biological Stress Response	Creation of modality	Bladder Cancer;Endometrial Cancer;Kidney Cancer ;Ovarian Cancer ;Skin Cancer (non-melanoma);Small Intestine Cancer ;Stomach Cancer;Urinary System	Less cancer;More cure;Better quality of life		€	1.117.460,50
10698	Assessing Stromal Architecture with MR elastography to predict cytotoxic treatment efficacy in Pancreatic cancer (ASAP-study)	prof. Jaap Stoker	Academic Medical Center	Radiology	Clinical	Pancreatic Cancer	Better quality of life		€	722.431,40
10774	Randomized trial for the evaluation of erectile dysfunction after whole or partial gland prostate brachytherapy - (POWER)	dr. Bradley Pieters	Academic Medical Center	Radiation Oncology (Radiotherapy)	Clinical	Prostate Cancer	Better quality of life		€	710.837,00
10598	Phase I-II study of brentuximab vedotin plus R-DHAP in CD30 positive DLBCL: HOVON 136 Transplant BRaVE NHL	dr. Pieterella Lugtenburg	Erasmus University Medical Center Rotterdam	Hematology	Clinical	Non-Hodgkin's Lymphoma	More cure		€	179.030,00

10684	TRIANGLE. Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in Generalized mantle cell Lymphoma - a randomized European MCL network trial	dr. Jeanette Doorduijn	Erasmus University Medical Center Rotterdam	Hematology	Clinical	Non-Hodgkin's Lymphoma	More cure		€ 253.885,00
10690	PREHAB: Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications. Fit to fight.	dr. Gerrit Slooter	Maxima Medisch Centrum	Surgery	Clinical	Colon and Rectal Cancer	More cure; Better quality of life		€ 720.884,00
10665	Sustained treatment-free remission in CML: prospective study comparing nilotinib versus imatinib with switch to nilotinib in absence of optimal response.	dr. Jeroen Janssen	VU University Medical Centre	Hematology (VUmc CCA)	Clinical	Leukemia	More cure; Better quality of life		€ 345.096,00
10668	Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail NDMM (HO143)	prof. Sonja Zweegman	VU University Medical Centre	Hematology (VUmc CCA)	Clinical	Blood Cancer ; Myeloma	More cure; Better quality of life		€ 627.649,00

Total funding Consortia (10 projects): € 6.517.591,20

UNIQUE HIGH RISK PROJECTS

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Tumor type	Mission Goal(s)	Assigned Funder	Approved budget
10764	Inducing and sustaining anti-tumor immunity by chemo-radiotherapy	dr. Inge Verbrugge	The Netherlands Cancer Institute	Immunology	Basic research	Head and Neck Cancer	Basic research; More cure	Alpe d'HuZes	€ 151.857,20
10832	A novel functional genomics approach to reveal crucial genetic events in human retinoblastoma carcinogenesis.	dr. Josephine Dorsman	VU University Medical Centre	Clinical Genetics (VUmc CCA)	Basic research	Retinoblastoma	Basic research; Less cancer; More cure	Alpe d'HuZes	€ 200.792,00
10611	Radiomics for the prediction of response to neoadjuvant treatment in rectal carcinoma	prof. Regina Beets-Tan	The Netherlands Cancer Institute	Diagnostic Oncology	Credentialing	Colon and Rectal Cancer	Basic research; Better quality of life	Alpe d'HuZes	€ 152.565,40
10820	Targeting oxLDL: a novel complementary intervention to increase cancer therapy efficacy	dr. Jan Theys	Maastricht UMC+ (Maastricht University)	GROW, School for Oncology and Developmental Biology	Creation of modality	Breast Cancer; Colon and Rectal Cancer; Liver Cancer ; Pancreatic Cancer	More cure; Better quality of life	Alpe d'HuZes	€ 149.944,50
10660	Organoid cultures and organoid-initiated metastasis models to study metastatic human colon cancer with microsatellite instability	prof. Onno Kranenburg	UMC Utrecht	UMC Utrecht Cancer Center	Creation of modality	Gastrointestinal Tract	Basic research; More cure	Alpe d'HuZes	€ 153.753,90
10559	Myeloid cell reprogramming in the context of radioiodine therapy in patients with non-medullary thyroid carcinoma	dr. Romana Netea-Maier	Radboud University Medical Center	Internal Medicine	Clinical	Thyroid Cancer	Basic research; More cure	Alpe d'HuZes	€ 151.946,00
10653	Mapping immunosuppressive cascades in breast cancer patients treated with immunotherapy	dr. Marleen Kok	The Netherlands Cancer Institute	Medical Oncology	Clinical	Breast Cancer	More cure	Alpe d'HuZes	€ 160.693,00
10810	Improving non-invasive assessment of aggressiveness and staging of localized prostate cancer with 7T-MRI and 68Ga-PSMA PET/CT	dr. Catalina Arteaga de Castro	UMC Utrecht	Imaging	Clinical	Prostate Cancer	More cure; Better quality of life	Alpe d'HuZes	€ 151.029,40

Total Funding Unique High Risk Projects (8 projects): € 1.272.581,40

Total funding CALL 2016-II: € 26.216.644,39

OVERVIEW

Research tracks & research phases

	Number of projects	Funding
Exploration track	20	€ 9.951.423,74
Basic research	15	€ 7.568.201,14
Credentialing	5	€ 2.383.222,60
Development track	32	€ 16.265.220,65
Creation of modality	13	€ 7.231.214,75
Preclinical	1	€ 699.474,00
Clinical	18	€ 8.334.531,90
Total	52	€ 26.216.644,39

Funding types & research phases

	Number of projects	Funding
Research Projects	28	€ 15.352.449,65
Basic research	9	€ 5.104.784,00
Credentialing	4	€ 2.230.657,20
Creation of modality	7	€ 3.459.720,75
Preclinical	1	€ 699.474,00
Clinical	7	€ 3.857.813,70
Young Investigator Grants	6	€ 3.074.022,14
Basic research	4	€ 2.110.767,94
Creation of modality	1	€ 510.016,80
Clinical	1	€ 453.237,40
Consortia	10	€ 6.517.591,20
Creation of modality	3	€ 2.957.778,80
Clinical	7	€ 3.559.812,40
Unique High Risk Projects	8	€ 1.272.581,40
Basic research	2	€ 352.649,20
Credentialing	1	€ 152.565,40
Creation of modality	2	€ 303.698,40
Clinical	3	€ 463.668,40
Total	52	€ 26.216.644,39